Literature DB >> 3441445

L364718, a new CCK antagonist, inhibits biological actions of CCK in conscious dogs.

R Hosotani1, P Chowdhury, D McKay, P L Rayford.   

Abstract

The effects of L364718, a new CCK receptor antagonist, on CCK-8 stimulated pancreatic secretion and PP release were examined in three conscious dogs with pancreatic fistulas. L364718 (20 nmol/kg) caused a potent inhibition of CCK-8 stimulated pancreatic protein, amylase and trypsin secretion but not of volume and bicarbonate secretion. Release of PP by CCK was also significantly suppressed by L364718. The degree of inhibition by L364718 was dependent upon the amount of CCK-8 infused. This study demonstrates that L364718 acts as a potent antagonist of CCK's action on pancreatic enzyme secretion and PP release in dogs and suggests that this agent might be a useful tool for studying the physiological role of CCK in conscious animals.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3441445     DOI: 10.1016/0196-9781(87)90137-9

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  2 in total

1.  L-364,718, a new CCK antagonist, inhibits postprandial pancreatic secretion and PP release in dogs.

Authors:  R Hosotani; P Chowdhury; P L Rayford
Journal:  Dig Dis Sci       Date:  1989-03       Impact factor: 3.199

2.  Lack of effect of the specific cholecystokinin receptor antagonist loxiglumide on cholecystokinin clearance from plasma in man.

Authors:  M C Jebbink; J B Jansen; A A Masclee; C B Lamers
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.